The problem of polypharmacy in heart failure

Current Cardiology Reports

Volumn 8, Issue 3, 2006, Pages 217-225

  Flesch, Markus ^b   Erdmann, Erland ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARDIAC GLYCOSIDE; CARVEDILOL; CORTICOSTEROID; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SPIRONOLACTONE; THYROID HORMONE; TORASEMIDE; UNINDEXED DRUG; VALSARTAN; WARFARIN;

CHRONIC LUNG DISEASE; CLINICAL TRIAL; COST CONTROL; DEFIBRILLATOR; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FLUID RETENTION; HEALTH CARE ACCESS; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE FIBROSIS; HOSPITAL COST; HUMAN; HYPERKALEMIA; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LACTIC ACIDOSIS; LOW DRUG DOSE; MEDICARE; META ANALYSIS; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHARMACEUTICAL CARE; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; QT PROLONGATION; REVIEW; RISK REDUCTION; SEX DIFFERENCE; SIDE EFFECT; SODIUM RETENTION; STROKE; SYSTEMATIC REVIEW; WATER RETENTION;

CARDIOVASCULAR AGENTS; CHRONIC DISEASE; DRUG INTERACTIONS; EUROPE; GUIDELINE ADHERENCE; HEART FAILURE, CONGESTIVE; HUMANS; POLYPHARMACY; PRACTICE GUIDELINES; RISK FACTORS; SEX FACTORS;

EID: 33646381889     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-006-0037-7     Document Type: Review

References (61)

1. Withering W: An Account of the Foxglove and Some of its Medicinal Uses. London: J and J Robinson; 1785.
2. Group DTDI: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533.
3. Schwinger RHG: Therapie der chronischen Herzinsuffizienz mit Diuretika. In Herzinsuffizienz. Edited by Erdmann E. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2005:265-299.
4. Erdmann E: Therapie der Herzinsuffizienz mit ACE-Hemmern. In Herzinsuffizienz. Edited by Erdmann B. Stuttgart: Wissenschaftiche Verlagsgesellschaft; 2005:314-326.
5. Erdmann E: Therapie der chronischen Herzinsuffizienz mit Beta-Blockern. In Herzinsuffizienz. Edited by Erdmann E. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2005:386-395.
6. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
7. Pitt B, Remme W, Zannad F, et al.: Eplerenone Post-Acute Myocardial Infarction Heart Failure E, Survival Study I. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
8. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of Iosartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582-1587.
9. Granger CB, McMurray JJ, Yusuf S. et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776.
10. McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
11. Swedberg K, Cleland J, Dargie H, et al.: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26:1115-1140.
12. Hunt SA: American College of Cardiology, American Heart Association Task Force on Practice Guidelines. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005, 46:e1-e82.
13. Taylor AL, Ziesche S, Yancy C, et al.: African-American Heart Failure Trial I. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
14. Komajda M, Lapuerta P, Hermans N, et al.: Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 2005, 26:1653-1659.
15. Flesch M, Komajda M, Lapuerta P, et al.: Leitliniengerechte Herzinsuffizienzbehandlung in Deutschland - Ergebnisse der MAHLER-Studie. Dtsch Med Wochenschr 2005, 130:2191-2197.
16. Masoudi PA, Rathore SS, Wang Y, et al.: National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004, 110:724-731.
17. Masoudi FA, Baillie CA, Wang Y, et al.: The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med 2005, 165:2069-2076.
18. Cohn JN, Tognoni G: Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345: 1667-1675.
19. Jong P, Demers C, McKelvie RS, Liu PP: Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002, 39:463-470.
20. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999, 359:9-13.
21. Effect of metoprolol CR/XL in chronic heart failure. Lancet 1999, 353:2001-2007.
22. Cowper PA, DeLong ER, Whellan DJ, et al.: Economic effects of beta-blocker therapy in patients with heart failure. Am J Med 2004, 116:104-111.
23. Stewart S, McMurray JJ, Hebborn A, et al.: Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom. Int J Cardiol 2005, 100:143-149.
24. Stehlik J, Taylor DO: And an ARB makes nine: polypharmacy in patients with heart failure. Cleve Clin J Med 2004, 71:674-677.
25. Yusuf S, Ostergren JB, Gerstein HC, et al.: Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005, 112:48-53.
26. Flather MD, Shibata MC, Coats AJ, et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26:215-225.
27. Packer M, Coats AJ, Fowler MB, et al.: Carvedilol Prospective Randomized Cumulative Survival Study G. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
28. Wikstrand J, Hjalmarson A, Waagstein F, et al.: Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002, 40:491-498.
29. Gottlieb SS, Fisher ML, Kjekshus J, et al.: Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation 2002, 105:1182-1188.
30. Delles C, Schmieder RE: The kidney in congestive heart failure: renal adverse event rate of treatment. J Cardiovasc Pharmacol 2001, 38:99-107.
31. Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan in Acute Myocardial Infarction Trial I. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
32. Juurlink DN, Mamdani MM, Lee DS, et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543-551.
33. Havranek EP, Masoudi FA, Westfall KA, et al.: Spectrum of heart failure in older patients: results from the National Heart Failure project. Am Heart J 2002, 143:412-417.
34. Amabile CM, Spencer AP: Keeping your patient with heart failure safe: a review of potentially dangerous medications [erratum appears in Arch Intern Med 2004, 164:1464]. Arch Intern Med 2004, 164:709-720.
35. Cleland JG, Findlay I, Jafri S, et al.: The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004, 148:157-164.
36. Nawarskas JJ, Spinler SA: Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors. Pharmacotherapy 2000, 20:698-710.
37. Page J, Henry D: Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000, 160:777-784.
38. Whelton A, Fort JG, Puma JA, et al.: Cyclooxygenase-2 - specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Therapeut 2001, 8:85-95.
39. Packer M, O'Connor CM, Ghali JK, et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996, 335:1107-1114.
40. Cohn JN, Ziesche S, Smith R, et al.: Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997, 96:856-863.
41. Elkayam U, Amin J, Mehra A, et al.: A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990, 82:1954-1961.
42. Cohn JN, Pfeffer MA, Rouleau J, et al.: Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003, 5:659-667.
43. Kjekshus J, Dunselman P, Blideskog M, et al.: A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005, 7:1059-1069.
44. Mettauer B, Rouleau JL, Burgess JH: Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure. Am Heart J 1985, 109:840-847.
45. Bouvy ML, Heerdink ER, De Bruin ML, et al.: Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Arch Intern Med 2000, 160:2477-3480.
46. Webb DJ, Freestone S, Allen MJ, Muirhead GJ: Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999, 83:21C-28C.
47. Leibovitz A, Bilchinsky T, Gil I, Habot B: Elevated serum digoxin level associated with coadministered fluoxetine. Arch Intern Med 1998, 158:1152-1153.
48. Fowles RE, Cloward TV, Yowell RL: Endocardial fibrosis associated with fenfluramine-phentermine. N Engl J Med 1998, 338:1316.
49. Kottkamp H, Budde T, Lamp B, et al.: Clinical significance and management of ventricular arrhythmias in heart failure. Eur Heart J 1994, 15(Suppl D):155-163.
50. Echt DS, Liebson PR, Mitchell LB, et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781-788.
51. Hallstrom AP, Anderson JL, Carlson M, et al.: Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. Am Heart J 1995, 130:71-79.
52. Flaker GC, Blackshear JL, McBride R, et al.: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992, 20:527-532.
53. Waldo AL, Camm AJ, deRuyter H, et al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996, 348:7-12.
54. Bardy GH, Lee KL, Mark DB, et al.: Sudden Cardiac Death in Heart Failure Trial I. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225-237.
55. Straus SM, Sturkenboom MC, Bleumink GS, et al.: Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005, 26:2007.
56. Rathore SS, Wang Y, Krumholz HM: Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002, 347:1403-1411.
57. Drici MD, Clement N: Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001, 24:575-585.
58. Mann DL, McMurray JJ, Packer M, et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594-1602.
59. Packer M, Califf RM, Konstam MA, et al.: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002, 106:920-926.
60. Packer M, McMurray J, Massie BM, et al.: Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005, 11:12-20.
61. Flesch M, Hoper A, Dell'Italia L, et al.: Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2003, 108:598-604.